Skip to main content
Nageatte Ibrahim, MD, Oncology, Philadelphia, PA

NageatteIbrahimMD(She/Her)

[Pronunciation: Najat]

Oncology • Philadelphia, PA

Melanoma

Chief Medical Officer, Oncology, Innovent Biologics

Join to view full profile

Dr. Ibrahim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Ibrahim's full profile

Already have an account?

  • Office

    Remote location
    Philadelphia, PA 19131
    Phone+1 267-235-6413

Education & Training

  • Tufts Medical Center
    Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
  • Eastern Virginia Medical School
    Eastern Virginia Medical SchoolResidency, Internal Medicine, 2004 - 2005
  • Drexel University College of Medicine/Hahnemann University Hospital
    Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 2002 - 2004
  • Drexel University College of Medicine
    Drexel University College of MedicineClass of 2002

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2014 - 2024
  • MA State Medical License
    MA State Medical License 2006 - 2021
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma  
    Igor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology

Authored Content

  • Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
  • Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
  • Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018

Press Mentions

  • Immunotherapy Drug Benefits Patients with High-Risk Local Melanomas
    Immunotherapy Drug Benefits Patients with High-Risk Local MelanomasSeptember 18th, 2021

Professional Memberships

Dr. Nageatte Ibrahim, Dr. Nageatte Ibrahim, MD, Dr. N Ibrahim